CA3164013A1 - Compositions for managing chronic obstructive pulmonary disease - Google Patents

Compositions for managing chronic obstructive pulmonary disease Download PDF

Info

Publication number
CA3164013A1
CA3164013A1 CA3164013A CA3164013A CA3164013A1 CA 3164013 A1 CA3164013 A1 CA 3164013A1 CA 3164013 A CA3164013 A CA 3164013A CA 3164013 A CA3164013 A CA 3164013A CA 3164013 A1 CA3164013 A1 CA 3164013A1
Authority
CA
Canada
Prior art keywords
chronic obstructive
obstructive pulmonary
pulmonary disease
alveolar
increased
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3164013A
Other languages
English (en)
French (fr)
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Sarang Bani
Anjali Pandey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3164013A1 publication Critical patent/CA3164013A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3164013A 2020-01-17 2021-01-16 Compositions for managing chronic obstructive pulmonary disease Pending CA3164013A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062962343P 2020-01-17 2020-01-17
US62/962,343 2020-01-17
US202063126920P 2020-12-17 2020-12-17
US63/126,920 2020-12-17
PCT/US2021/013763 WO2021146648A1 (en) 2020-01-17 2021-01-16 Compositions for managing chronic obstructive pulmonary disease

Publications (1)

Publication Number Publication Date
CA3164013A1 true CA3164013A1 (en) 2021-07-22

Family

ID=76856592

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3164013A Pending CA3164013A1 (en) 2020-01-17 2021-01-16 Compositions for managing chronic obstructive pulmonary disease

Country Status (9)

Country Link
US (1) US11925606B2 (enExample)
EP (1) EP4090340B1 (enExample)
JP (1) JP7746272B2 (enExample)
KR (1) KR20220128382A (enExample)
CN (1) CN115175672B (enExample)
AU (1) AU2021207536B2 (enExample)
BR (1) BR112022014114A2 (enExample)
CA (1) CA3164013A1 (enExample)
WO (1) WO2021146648A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023554642A (ja) * 2020-12-17 2023-12-28 サミ－サビンサ グループ リミテッド ビスデメトキシクルクミン組成物の抗肥満能
WO2022203721A1 (en) * 2021-03-25 2022-09-29 Muhammed Majeed Compositions and methods for inhibiting proteolytic activation of viruses
RS20220433A1 (sr) 2022-05-11 2023-11-30 Milan Prokin Višeciljni antivirusni dodatak ishrani

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20100179103A1 (en) * 2008-07-21 2010-07-15 Ketan Desai Curcumin cyclodextrin combination for preventing or treating various diseases
US8486909B2 (en) * 2009-06-24 2013-07-16 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
EP2475380A1 (en) * 2009-09-11 2012-07-18 Protaffin Biotechnologie AG Composition for treatment of cxcl8-mediated lung inflammation
WO2012047674A2 (en) * 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
ITMI20132169A1 (it) * 2013-12-20 2015-06-21 Thompson S R L Composizione per la prevenzione ed il trattamento della bpco e della sintomatologia correlata
JP2017516764A (ja) * 2014-04-18 2017-06-22 オムニアクティブ ヘルス テクノロジーズ リミテッド クルクミン組成物及びその使用
WO2016145159A1 (en) * 2015-03-10 2016-09-15 The Research Foundation For The State University Of New York Chemically modified curcumins for use in the production of lipoxins
JP6688009B2 (ja) * 2015-04-15 2020-04-28 長谷川　浩二 酸化変性ｌｄｌ複合体抑制剤
CN105998043B (zh) * 2016-07-01 2018-11-27 吉林大学 槐属双苷在制备防治慢性阻塞性肺疾病药物中的应用

Also Published As

Publication number Publication date
US11925606B2 (en) 2024-03-12
CN115175672A (zh) 2022-10-11
AU2021207536B2 (en) 2025-04-10
NZ790708A (en) 2025-05-02
CN115175672B (zh) 2024-07-02
WO2021146648A1 (en) 2021-07-22
BR112022014114A2 (pt) 2022-09-13
JP2023512489A (ja) 2023-03-27
AU2021207536A1 (en) 2022-08-11
KR20220128382A (ko) 2022-09-20
US20210220290A1 (en) 2021-07-22
EP4090340A1 (en) 2022-11-23
EP4090340B1 (en) 2026-05-06
EP4090340A4 (en) 2024-02-21
JP7746272B2 (ja) 2025-09-30

Similar Documents

Publication Publication Date Title
Fan et al. PM2. 5 increases susceptibility to acute exacerbation of COPD via NOX4/Nrf2 redox imbalance-mediated mitophagy
AU2021207536B2 (en) Compositions for managing chronic obstructive pulmonary disease
Xiong et al. PM2. 5-induced lung injury is attenuated in macrophage-specific NLRP3 deficient mice
McMillan et al. Prolonged allergen challenge in mice leads to persistent airway remodelling
da Silva et al. Ethanolic extract of roots from Arctium lappa L. accelerates the healing of acetic acid-induced gastric ulcer in rats: Involvement of the antioxidant system
Lee et al. Camellia japonica oil suppressed asthma occurrence via GATA-3 & IL-4 pathway and its effective and major component is oleic acid
Lee et al. Grape seed proanthocyanidin extract attenuates allergic inflammation in murine models of asthma
Kang et al. Dai-Huang-Fu-Zi-Tang alleviates pulmonary and intestinal injury with severe acute pancreatitis via regulating aquaporins in rats
Faddah et al. Role of quercetin and arginine in ameliorating nano zinc oxide-induced nephrotoxicity in rats
Shi et al. Mitochondrial dysfunction: an emerging link in the pathophysiology of cardiorenal syndrome
Skevaki et al. Rhinovirus-induced basic fibroblast growth factor release mediates airway remodeling features
JP4571952B2 (ja) 抗アレルギー組成物及び関連方法
Li et al. S-Allylmercaptocysteine attenuates Bleomycin-induced pulmonary fibrosis in mice via suppressing TGF-β1/Smad and oxidative stress pathways
Lyu et al. Anti‐inflammatory effects of reticuline on the JAK2/STAT3/SOCS3 and p38 MAPK/NF‐κB signaling pathway in a mouse model of obesity‐associated asthma
Lee et al. Distribution of RANTES and interleukin-5 in allergic nasal mucosa and nasal polyps
Chatterjee et al. Synergistic therapeutic potential of dexamethasone and L-arginine in lipopolysaccharide-induced septic shock
Saleem et al. Polystichum braunii ameliorates airway inflammation by attenuation of inflammatory and oxidative stress biomarkers, and pulmonary edema by elevation of aquaporins in ovalbumin-induced allergic asthmatic mice
Zhang et al. Tanshinone IIA attenuates seawater aspiration-induced lung injury by inhibiting macrophage migration inhibitory factor
Bao et al. Baicalin ameliorates radiation‐induced lung injury by inhibiting the CysLTs/CysLT1 signaling pathway
Ali et al. Modulation of immunological, biochemical, and histopathological changes of Airway Remodeling by Withania somnifera in an experimental model of allergic asthma in rats
Chin et al. Orally delivered perilla (Perilla frutescens) leaf extract effectively inhibits SARS-CoV-2 infection in a Syrian hamster model
Carr et al. Distribution of immunoreactive endothelin in the lungs of mice during respiratory viral infection
Zhan et al. Study of the expression of GABA
US20230124965A1 (en) Plant composition, traditional chinese medicine composition and use thereof
Chen et al. Silymarin attenuates cardiac injury and inflammation in adjuvant-induced rheumatoid arthritis rats through activation of the Nrf2/SLC7A11/GPX4 signaling pathway

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220706

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241227

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241227

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250123

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250502

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250616

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250616

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260114